Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Bavituximab in NSCLC
NCT02673814Phase 2Withdrawn
- Sponsor
- Avid Bioservices, Inc.
- Start
- Feb 2016
- Primary completion
- Apr 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of bavituximab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Avid Bioservices, Inc. Primary endpoint: Objective Response Rate at 24 months. Planned start Feb 2016; status: withdrawn.
02
Drugs
bavituximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02673814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673814.